Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
Cynthia Matossian,William Trattler,Jennifer Loh
DOI: https://doi.org/10.2147/OPTH.S308088
2021-05-12
Clinical Ophthalmology
Abstract:Cynthia Matossian, 1 William Trattler, 2 Jennifer Loh 3 1 Matossian Eye Associates, Pennington, NJ, USA; 2 Center for Excellence in Eye Care, Miami, FL, USA; 3 Loh Ophthalmology Associates, Miami, FL, USA Correspondence: Cynthia Matossian Matossian Eye Associates, 2 Capital Way, Ste 326, Pennington, NJ, 08534, USA Tel +1 215-230-9200 Email Purpose: To evaluate the efficacy of topical cyclosporine 0.1% in chondroitin sulfate emulsion for the treatment of dry eye. Methods: This retrospective multicenter study included 100 eyes of 50 dry eye patients aged ≥ 18 years, with preoperative ocular surface disease index (OSDI) score > 12 or corneal staining grade > 1 (in either eye) who underwent dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate emulsion (Klarity-C, ImprimisRx) for 3 months. Postoperative evaluation included comparison of the changes in OSDI score and corneal staining grade after 3 months of treatment from baseline. Results: From baseline to 3 months, a statistically significant improvement in mean OSDI scores (38.19 vs 24.18, p < 0.001) as well as mean corneal staining grade (3.62 vs 2.20, p < 0.001) was observed. The proportion of subjects with severe dry eye decreased from 62% to 20% and more than one-third (34%) of patients were in the normal OSDI range. The percentage of eyes with corneal staining grade of 2 or 3 decreased from 21% (baseline) to 8% at 3 months; 50% of the eyes had corneal staining grade of 0. The treatment was found to be safe with no adverse events observed in the study. Conclusion: Dry eye treatment with twice daily cyclosporine 0.1% in chondroitin sulfate emulsion was found to be safe and effective in reducing signs and symptoms of dry eye. Keywords: dry eye treatment, dry eye disease, cyclosporine 0.1%, Klarity-C, immunosuppressive agent DED Dry eye is a chronic multifactorial disease of the tear film and ocular surface that results in symptoms of ocular discomfort, affects vision, and negatively impacts patients' quality of life. 1 Lubricating drops are usually the first line of treatment to restore ocular surface homeostasis. 2 While tear supplementation may provide short term symptomatic relief in mild dry eye cases, these methods are generally palliative and inadequate at resolving moderate to severe dry eye symptoms. 3 , 4 Increased osmolarity of the tear film and inflammation of the ocular surface have been recognized as core mechanisms underlying the development of dry eye disease (DED). 5 As such, advanced DED cases benefit from topical anti-inflammatory therapies. 6 Corticosteroids are potent anti-inflammatory agents that have been found to be quite effective in reducing ocular surface inflammation. However, given the risk of cataract formation, ocular hypertension, and glaucoma with long-term use of steroids, these medications are typically not considered suitable for prolonged treatment of chronic DED. 7 , 8 Cyclosporine is an anti-inflammatory and immunosuppressive agent that has been in use for more than 15 years to reduce ocular surface inflammation and improve tear film dynamics. 9–11 The safety profile of cyclosporine is well established. 4 , 10 , 12 This lipophilic drug functions through the inhibition of calcineurin, preventing the activation of T lymphocytes and associated release of proinflammatory mediators. 13 Cyclosporine 0.05% ophthalmic emulsion has been shown to increase tear production and reduce signs and symptoms of DED. 4 , 14–18 Although the recommended dosing regimen of this medication is two times a day, there is some evidence to suggest that the clinical efficacy of the medication increases with more frequent dosing or with higher cyclosporine concentrations. 3 , 7 , 10 , 12 , 19 , 20 In the present study, the efficacy of a preservative-free, high-concentration cyclosporine (0.1%) in a novel chondroitin sulfate vehicle was evaluated for the reduction of signs and symptoms of dry eye. This retrospective multicenter study included case records for 50 patients (100 eyes) who received topical cyclosporine 0.1% in chondroitin sulfate emulsi -Abstract Truncated-